Press-release for stocks related to clinical-trials-phase-iii for SNY

tags : Clinical-trials-phase-iii symbols : SNY

save search

FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
fda cancer blood therapy

Experts Take a ‘Wait and See’ Approach as BTK Inhibitors Stumble in MS
Published: 2024-01-29 (Crawled : 07:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -9.25% | O: 0.12% H: 0.0% C: 0.0%

Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
Published: 2023-12-21 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -6.68% | O: -0.08% H: 0.0% C: 0.0%
lung axes cancer trial sanofi

Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.62% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.4% | O: 1.04% H: 0.17% C: 0.11%
dupixent positive copd results sanofi

Early October Sees Torrid Pace of Biotech M&A—Will It Continue?
Published: 2023-10-13 (Crawled : 21:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -17.13% | O: -0.26% H: 0.0% C: 0.0%
biotech

Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -15.85% | O: -0.97% H: 0.0% C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -8.67% | O: -1.87% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 24.04% | O: 0.54% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -17.01% | O: 0.14% H: 0.0% C: 0.0%
trial

Incyte’s Opzelura Clears Phase III Trial in Pediatric Atopic Dermatitis
Published: 2023-07-12 (Crawled : 15:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -12.3% | O: -0.89% H: 0.0% C: 0.0%
opzelura dermatitis trial

Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Published: 2023-06-09 (Crawled : 15:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.9% | O: 2.58% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -11.7% | O: -0.7% H: 0.0% C: 0.0%
crispr

Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
Published: 2023-05-12 (Crawled : 14:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -15.64% | O: 0.26% H: 0.0% C: 0.0%
report rsv

Travere's Sparsentan Stumbles in Phase III Rare Kidney Disease Study
Published: 2023-05-03 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -14.78% | O: 0.71% H: 0.0% C: 0.0%
rare disease kidney study

Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts
Published: 2023-04-27 (Crawled : 15:20) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -21.24% | O: -3.56% H: 0.0% C: 0.0%
sanofi

Merck’s BTK Inhibitor Evobrutinib Slapped with Partial Clinical Hold
Published: 2023-04-13 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -18.15% | O: -1.1% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -18.62% | O: 0.29% H: 0.0% C: 0.0%

Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
Published: 2023-04-04 (Crawled : 09:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -16.36% | O: -0.1% H: 0.0% C: 0.0%
lancet potential

Dupixent Clears Phase III in Bid to Become First Biologic for COPD
Published: 2023-03-23 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -5.09% | O: 5.54% H: 0.96% C: 0.96%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -6.78% | O: 6.53% H: 0.56% C: -0.54%
dupixent copd

Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma
Published: 2023-03-09 (Crawled : 14:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.38% | O: 0.22% H: 0.1% C: -1.36%
trials therapeutics

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Published: 2023-03-02 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.38% | O: 0.16% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.68% | O: -0.76% H: 1.58% C: 1.58%
treatment children potential study

Pfizer Gains on Astra and Sanofi in Infant RSV Prevention Race
Published: 2023-02-21 (Crawled : 00:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.9% | O: 0.79% H: 0.0% C: 0.0%
rsv sanofi

Pfizer Gains on Astra and Sanofi in Maternal RSV Vaccine Race
Published: 2023-02-21 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology